Voyager Therapeutics マネジメント

マネジメント基準チェック /34

Voyager Therapeuticsの CEO はAl Sandrockで、 Mar2022年に任命され、の在任期間は 2.67年です。の年間総報酬は$ 3.17Mで、 19.7%給与と80.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.12%を直接所有しており、その価値は$ 354.42K 。経営陣と取締役会の平均在任期間はそれぞれ2.2年と4.8年です。

主要情報

Al Sandrock

最高経営責任者

US$3.2m

報酬総額

CEO給与比率	19.7%
CEO在任期間	2.7yrs
CEOの所有権	0.1%
経営陣の平均在職期間	2.2yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Nov 18

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Oct 17

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Aug 26

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 09

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Aug 08

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Jun 05

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Mar 15

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Mar 08

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Mar 04

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Jan 04

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Oct 04

Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates

May 12

Voyager Does A Reboot After First Generation Failures

Mar 25

CEO報酬分析

Voyager Therapeutics の収益と比較して、Al Sandrock の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$26m
Jun 30 2024	n/a	n/a	US$9m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$3m	US$624k	US$132m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$96m
Mar 31 2023	n/a	n/a	US$99m
Dec 31 2022	US$7m	US$525k	-US$46m

報酬と市場: Alの総報酬 ($USD 3.17M ) は、 US市場 ($USD 2.22M ) の同規模の企業の平均を上回っています。

報酬と収益: Alの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Al Sandrock (66 yo)

2.7yrs

在職期間

US$3,172,433

報酬

Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph D., served as Director at Verge Analytics, Inc. since February 2022. He served as Member of Scientific Advisory Board at Camp4 Therapeutics Corporatio...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Alfred Sandrock	President	2.7yrs	US$3.17m	0.12% $ 354.4k
Robin Swartz	COO & Acting Chief Business Officer	no data	US$1.38m	0.062% $ 189.9k
Jacquelyn Sandell	Chief Legal Officer	1.3yrs	US$1.91m	0.026% $ 80.8k
Krystof Bankiewicz	Founder	no data	データなし	データなし
Guangping Gao	Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Mark Kay	Founder	no data	データなし	データなし
Phillip Zamore	Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Nathan Jorgensen	Chief Financial Officer	less than a year	データなし	データなし
Todd Carter	Chief Scientific Officer	2.2yrs	データなし	0.16% $ 494.2k
Michelle Smith	Chief Human Resources Officer	4.2yrs	データなし	データなし
Trista Morrison	Chief Corporate Affairs Officer & Chief of Staff to the CEO	2.8yrs	データなし	データなし
Toby Ferguson	Chief Medical Officer	less than a year	データなし	データなし

2.2yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: VYGRの経営陣は経験豊富であると考えられます ( 2.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Alfred Sandrock	President	2.8yrs	US$3.17m	0.12% $ 354.4k
Guangping Gao	Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Phillip Zamore	Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Dinah Sah	Consultant & Member of Scientific Advisory Board	5.4yrs	US$1.81m	データなし
James Arthur Geraghty	Independent Director	10.8yrs	US$263.78k	0.10% $ 307.9k
Glenn Pierce	Independent Director	7.8yrs	US$248.78k	0.040% $ 122.9k
Steven Hyman	Independent Director	9.2yrs	US$255.78k	0% $ 0
Michael Higgins	Independent Chairman of the Board	9.3yrs	US$281.28k	0.057% $ 176.6k
Catherine Mackey	Independent Director	2.3yrs	US$250.78k	0% $ 0
Jude Onyia	Director	1.8yrs	US$452.32k	0.0053% $ 16.4k
Grace Colon	Independent Director	1.8yrs	US$432.23k	0% $ 0
Nancy Vitale	Independent Director	4.2yrs	US$255.28k	0% $ 0

4.8yrs

平均在職期間

64.5yo

平均年齢

経験豊富なボード: VYGRの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Voyager Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Recent updates

Investor sentiment deteriorates as stock falls 23%

Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Investor sentiment deteriorates as stock falls 19%

Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified

Investor sentiment improves as stock rises 20%

Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround

Consensus revenue estimates increase by 42%

Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index

Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024

Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis

Consensus revenue estimates increase by 29%

Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting

Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Investor sentiment improves as stock rises 16%

Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

President recently sold US$119k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise

Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

Consensus revenue estimates fall by 21%

What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Investor sentiment improves as stock rises 18%

President recently sold US$97k worth of stock

President notifies of intention to sell stock

Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research

New minor risk - Share price stability

Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Financial Officer recently sold US$95k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Chief Science Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 25%

Price target increased by 9.8% to US$11.17

Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President recently sold US$58k worth of stock

Chief Operating Officer recently sold US$126k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$8.20

Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023

Consensus revenue estimates increase by 170%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families

Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target

Consensus forecasts updated

マネジメント基準チェック /34